feb 13, 2018: 11 a.m. - 11:55 a.m.
As the U.S. tax code experiences its greatest changes in decades, the financial assumptions underlying investors’ valuations will shift significantly, creating some new advantages and disadvantages within the biopharma community. This session will explain in depth the implications for pre-market and for commercial biopharma companies of changes to R&D credits, orphan drug credits, repatriation conditions, and other key dimensions of the tax rules for 2018, plus where policy adjustments might be worth recommending.
Moderator: Cameron Arterton, Vice President, Tax Policy, Emerging Companies, Biotechnology Innovation Organization (BIO)
Brendan P. Cox, Partner, Ernst & Young LLP
Robert Masella, Partner, Shearman & Sterling
Andrew J. Silverman, Government Analyst—Tax, Bloomberg Intelligence